Trump administration selects five coronavirus vaccine candidates as finalists: NYT
The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.
CONCLUSION: The modified Bateman SIZ model has been verified and used to predict the course of the COVID-19 pandemic in Heidelberg. Lockdown measures alone are insufficient to control the pandemic during 2021. Vaccination, diagnostic tests, and use of the Corona-Warn-App with quarantine could successfully control the spread of the coronavirus infection in the community. The Corona-Warn-App applied correctly may be the most effective. The model showed that vaccination with 50% efficacy is almost as effective as vaccination with 100% efficacy. PMID: 32646540 [PubMed - as supplied by publisher]
Publication date: 15 September 2020Source: Life Sciences, Volume 257Author(s): Ariane Sternberg, Cord Naujokat
This blog has closed –please keep following our live coverage here12.50amBSTThis blog has closed – thanks for following. Coverage continues at ourlatest coronavirus live blog.12.27amBSTGood morning, good evening, hello, wherever you might be. This isHelen Davidson taking the reins of the blog for the next few hours. Thanks to my colleagues for their coverage.We ’ll be starting a new blog shortly, but in the meantime here is some more news on the vaccine front.Continue reading...
Billionaire philanthropist Bill Gates has called for COVID-19 drugs and an eventual vaccine to be made available to countries and people that need them most, not to the "highest bidder," saying relying on market forces would prolong the deadly pandemic.
CONCLUSIONS: It is anticipated that this review would certainly assist the public in general and scientific community in particular to recognize and effectively deal with COVID-19, providing a reference guide for futuristic studies. PMID: 32651959 [PubMed - as supplied by publisher]
More research emerged this week in potential support of using the tuberculosis vaccine Bacillus Calmette-Guerin (BCG) as a tool in the fight against coronavirus.
The market finished higher as investors cheered positive coronavirus vaccine news.
Condition: Coronavirus Interventions: Biological: Recombinant new coronavirus vaccine (CHO cell) low-dose group; Biological: Recombinant new coronavirus vaccine (CHO cells) high-dose group; Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Not yet recruiting
More than 140 teams of researchers are racing to develop a safe and effective coronavirus vaccineResearchers around the world are racing to develop a vaccine against Covid-19, withmore than 140 candidate vaccines now tracked by the World Health Organization (WHO).Continue reading...
US President Donald Trump has been pushing hard for an American vaccine against Covid-19. He's named the program Operation Warp Speed, which has many people worried that safety tests will be rushed. What are the prospects for an American vaccine against Covid-19? If the US is first, will it make its vaccines available to other countries? And what if it's not first? Three American vaccine experts talk with the BMJ about prospects for an American vaccine against the new coronavirus. Joining us are; Nicole Lurrie - senior lecturer at Harvard Medical School and a strategic adviser to the foundation working on global vacci...